KR100948281B1 - The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants - Google Patents
The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants Download PDFInfo
- Publication number
- KR100948281B1 KR100948281B1 KR1020090096162A KR20090096162A KR100948281B1 KR 100948281 B1 KR100948281 B1 KR 100948281B1 KR 1020090096162 A KR1020090096162 A KR 1020090096162A KR 20090096162 A KR20090096162 A KR 20090096162A KR 100948281 B1 KR100948281 B1 KR 100948281B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- plant
- group
- obesity
- herbal
- Prior art date
Links
- 235000005911 diet Nutrition 0.000 title claims abstract description 31
- 230000037213 diet Effects 0.000 title claims abstract description 28
- 238000000034 method Methods 0.000 title claims abstract description 18
- 239000000463 material Substances 0.000 title description 5
- 235000013376 functional food Nutrition 0.000 title description 3
- 239000000284 extract Substances 0.000 claims abstract description 46
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 239000012141 concentrate Substances 0.000 claims abstract description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000605 extraction Methods 0.000 claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 claims abstract description 12
- 239000000843 powder Substances 0.000 claims abstract description 12
- 239000000706 filtrate Substances 0.000 claims abstract description 11
- 238000001914 filtration Methods 0.000 claims abstract description 5
- 241000196324 Embryophyta Species 0.000 claims description 54
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 44
- 241000411851 herbal medicine Species 0.000 claims description 39
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 235000002789 Panax ginseng Nutrition 0.000 claims description 9
- 244000241838 Lycium barbarum Species 0.000 claims description 8
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 8
- 244000223014 Syzygium aromaticum Species 0.000 claims description 6
- 235000016639 Syzygium aromaticum Nutrition 0.000 claims description 6
- 240000001417 Vigna umbellata Species 0.000 claims description 6
- 235000011453 Vigna umbellata Nutrition 0.000 claims description 6
- 239000012676 herbal extract Substances 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 241001061264 Astragalus Species 0.000 claims description 5
- 235000006533 astragalus Nutrition 0.000 claims description 5
- 210000004207 dermis Anatomy 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 210000004233 talus Anatomy 0.000 claims description 5
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 239000012153 distilled water Substances 0.000 claims description 4
- 230000000378 dietary effect Effects 0.000 claims description 3
- 240000006927 Foeniculum vulgare Species 0.000 claims 1
- 235000015096 spirit Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 42
- 230000003579 anti-obesity Effects 0.000 abstract description 28
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 26
- 239000003814 drug Substances 0.000 abstract description 18
- 229940079593 drug Drugs 0.000 abstract description 11
- 235000012000 cholesterol Nutrition 0.000 abstract description 10
- 239000004480 active ingredient Substances 0.000 abstract description 9
- 230000036772 blood pressure Effects 0.000 abstract description 7
- 230000009467 reduction Effects 0.000 abstract description 6
- 238000011084 recovery Methods 0.000 abstract description 3
- 238000001035 drying Methods 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000001704 evaporation Methods 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 241000212314 Foeniculum Species 0.000 description 46
- 208000008589 Obesity Diseases 0.000 description 25
- 230000006870 function Effects 0.000 description 25
- 235000020824 obesity Nutrition 0.000 description 25
- 230000007423 decrease Effects 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 230000009471 action Effects 0.000 description 13
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 10
- MKMCJLMBVKHUMS-UHFFFAOYSA-N Coixol Chemical compound COC1=CC=C2NC(=O)OC2=C1 MKMCJLMBVKHUMS-UHFFFAOYSA-N 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- 239000004009 herbicide Substances 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
- 210000002700 urine Anatomy 0.000 description 7
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 6
- 102000043296 Lipoprotein lipases Human genes 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000008216 herbs Nutrition 0.000 description 6
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 230000037356 lipid metabolism Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102000005870 Coenzyme A Ligases Human genes 0.000 description 5
- 108010011449 Long-chain-fatty-acid-CoA ligase Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 240000007594 Oryza sativa Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 235000009200 high fat diet Nutrition 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000341 volatile oil Substances 0.000 description 5
- 102000000019 Sterol Esterase Human genes 0.000 description 4
- 108010055297 Sterol Esterase Proteins 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 210000001789 adipocyte Anatomy 0.000 description 4
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 4
- 229960001231 choline Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- -1 dibutylpropion Chemical compound 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 201000010063 epididymitis Diseases 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 125000005456 glyceride group Chemical group 0.000 description 4
- 229940093915 gynecological organic acid Drugs 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002363 herbicidal effect Effects 0.000 description 4
- 210000003630 histaminocyte Anatomy 0.000 description 4
- 210000005228 liver tissue Anatomy 0.000 description 4
- 235000005985 organic acids Nutrition 0.000 description 4
- 239000000419 plant extract Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 235000021314 Palmitic acid Nutrition 0.000 description 3
- 230000009102 absorption Effects 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000001671 coumarin Nutrition 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 229940072117 fennel extract Drugs 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 229930182470 glycoside Natural products 0.000 description 3
- 150000002338 glycosides Chemical class 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 3
- 208000004296 neuralgia Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 229950005143 sitosterol Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 235000018185 Betula X alpestris Nutrition 0.000 description 2
- 235000018212 Betula X uliginosa Nutrition 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 2
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 102000019280 Pancreatic lipases Human genes 0.000 description 2
- 108050006759 Pancreatic lipases Proteins 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 2
- 229940076810 beta sitosterol Drugs 0.000 description 2
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 2
- 229960003237 betaine Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 229960000956 coumarin Drugs 0.000 description 2
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000005265 energy consumption Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 229940025878 hesperidin Drugs 0.000 description 2
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 2
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229940116369 pancreatic lipase Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 230000001850 reproductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 2
- 229940032091 stigmasterol Drugs 0.000 description 2
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 2
- 235000016831 stigmasterol Nutrition 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 229920001864 tannin Polymers 0.000 description 2
- 239000001648 tannin Substances 0.000 description 2
- 235000018553 tannin Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- LPZCCMIISIBREI-JXMPMKKESA-N (Z)-24-ethylidenelophenol Chemical compound C[C@@H]1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CC/C(=C/C)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 LPZCCMIISIBREI-JXMPMKKESA-N 0.000 description 1
- BFSPAPKTIGPYOV-BQYQJAHWSA-N (e)-1-[4-(4-hydroxyphenyl)piperazin-1-yl]-3-thiophen-2-ylprop-2-en-1-one Chemical compound C1=CC(O)=CC=C1N1CCN(C(=O)\C=C\C=2SC=CC=2)CC1 BFSPAPKTIGPYOV-BQYQJAHWSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HCXVJBMSMIARIN-ZETWWWAOSA-N 24alpha-Ethyl-koprostanol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@@H]2[C@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C)C(C)C HCXVJBMSMIARIN-ZETWWWAOSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 240000007087 Apium graveolens Species 0.000 description 1
- 235000015849 Apium graveolens Dulce Group Nutrition 0.000 description 1
- 235000010591 Appio Nutrition 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 235000000832 Ayote Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010035563 Chloramphenicol O-acetyltransferase Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- DPQCZNIGGNJGTD-UHFFFAOYSA-N Chloride-(??)-2-Methylpentanoic acid Natural products CCCCCCC=CCCCCCCCCCC(=O)OC(C)C(C)OC(=O)CCCCCCCC=CCCCCCC DPQCZNIGGNJGTD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 241000548268 Citrus deliciosa Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- UDTUCCXZNVRBEJ-PBVFJORSSA-N Clove-3 Chemical compound C=12OC(C)=CC(=O)C2=C(O)C=C(O)C=1[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UDTUCCXZNVRBEJ-PBVFJORSSA-N 0.000 description 1
- DPQCZNIGGNJGTD-MVCBGFDASA-N Coixenolide Chemical compound CCCCCC\C=C\CCCCCCCCCC(=O)O[C@@H](C)[C@@H](C)OC(=O)CCCCCCC\C=C/CCCCCC DPQCZNIGGNJGTD-MVCBGFDASA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- 235000009854 Cucurbita moschata Nutrition 0.000 description 1
- 240000001980 Cucurbita pepo Species 0.000 description 1
- 235000009804 Cucurbita pepo subsp pepo Nutrition 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000208152 Geranium Species 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000028482 Hypothalamic disease Diseases 0.000 description 1
- 208000025282 Hypothalamo-pituitary disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 206010029216 Nervousness Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- SKPPEIDJGJGRGK-UHFFFAOYSA-N Panacen Natural products CCC1=CC=CC2=C1C1OC(C=C=CBr)CC1O2 SKPPEIDJGJGRGK-UHFFFAOYSA-N 0.000 description 1
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 235000014443 Pyrus communis Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229930188824 alisol Natural products 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- JZVFJDZBLUFKCA-UTQQLQBSSA-N alpha-spinasterol Natural products CC[C@H](C=C[C@H](C)[C@H]1CC[C@H]2C3=CC[C@@H]4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C JZVFJDZBLUFKCA-UTQQLQBSSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 description 1
- 229960002837 benzphetamine Drugs 0.000 description 1
- 229960003403 betaine hydrochloride Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- HOPSCVCBEOCPJZ-UHFFFAOYSA-N carboxymethyl(trimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)=O HOPSCVCBEOCPJZ-UHFFFAOYSA-N 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 230000006652 catabolic pathway Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- XMLNCADGRIEXPK-KUMOIWDRSA-M chembl2146143 Chemical compound [Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N+]2(C)C)C(=O)C(CO)C1=CC=CC=C1 XMLNCADGRIEXPK-KUMOIWDRSA-M 0.000 description 1
- 229910001430 chromium ion Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 229960003624 creatine Drugs 0.000 description 1
- 239000006046 creatine Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000001916 dieting Nutrition 0.000 description 1
- 230000037228 dieting effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000000077 insect repellent Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 210000001596 intra-abdominal fat Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960000436 phendimetrazine Drugs 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001197 polyacetylene Polymers 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000015136 pumpkin Nutrition 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 235000021309 simple sugar Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 229930193551 sterin Natural products 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 식물생약제를 이용한 다이어트용 식품의 제조방법에 관한 것으로 구체적으로는 종래 식물생약제나 한방제로된 다이어트식품의 문제점과 본 출원과 관련성이 있는 본원출원인의 국내등록특허(등록번호 제10-0891914호)의 상품화 과정에서 발생된 시행착오와 강원대학교 연구용역 결과보고서(회향을 함유하는 식물생약제 조성물의 항비만 건강효능검증에 관한 연구)를 검토하여 항비만의 주기능을 갖는 회향(Fennel 또는 Foeniculum Fractus)추출액을 주성분으로 하고 회향에 첨가하여 항비만기능에 상승효과를 부여하는 제1군의 식물생약제 추출액과 이와 같은 항비만작용에 따라 수반되어야하는 혈압강하, 콜레스테롤 감소, 원활한 대사작용 등의 보조적인기능을 수행하는 제2군의 식물생약제 추출액의 혼합추출액으로 되거나 혼합추출액을 동결건조하여 분말로된 식물생약제를 이용한 다이어트용 식품의 제조방법에 관한 것이다.The present invention relates to a method for manufacturing a diet food using a plant herbal medicine, and in particular, a domestic registered patent of the applicant of the present application which is related to the problems of the conventional dietary herbal food or herbal diet food and the present application (registration number 10-0891914). Fennel (Fennel or Foeniculum) having the main function of anti-obesity by reviewing trial and error that occurred during the commercialization process and research result report (study on anti-obesity health efficacy of plant herbal composition containing fennel) Fractus) The first group of plant herb extracts that contain synergistic effects and add synergistic effects to fennel, and supplements with blood pressure drop, cholesterol reduction, and smooth metabolism that must be accompanied by such anti-obesity effects. It becomes a mixed extract of the second group of plant herbal extracts that perform the functional function or lyophilizes the mixed extract. To a method of producing food for dieting by the herbal plants as a powder.
상기 본 발명 개발기술의 개요와 필요성을 언급하면,Referring to the outline and necessity of the present invention development technology,
현대인의 식생활 패턴변화인 단순당, 육류, 지방 등의 섭취증가로 인해 각종 만성성인질환의 유병율이 증가하고 있으며, 이러한 질병들은 역학적 연구들을 종합하여 볼 때 비만과 매우 밀접한 관련이 있는 것으로 나타났으며 최근 사회적으로나 경제적으로 그 심각성이 대두되고 있는 성인병의 예방 및 치료를 위하여 비만을 개선 또는 치유할 수 있는 과학적 연구개발이 시급한 설정이며,Increasing intake of simple sugars, meat, fats, etc., which are changes in the diet patterns of modern people, has increased the prevalence of various chronic human diseases, and these diseases are closely related to obesity. In order to prevent and treat adult diseases, which have recently become socially and economically serious, scientific research and development that can improve or cure obesity is urgently needed.
사람에게서 비만은 지나친 열량섭취, 내분비 장애, 운동부족, 유전적인 인자 등이 있지만 주된 발생기전은 에너지 섭취와 소비의 불균형으로 에너지소비효율이 나쁘면 지방축적에 의해 비만이 발생하고, 다른 특별한 원인 없이 섭취에너지에 비해 소비에너지가 적을 때 초래되는 단순성(본태성) 비만과 내분비질환(인슐린 의존성 당뇨병, cushing 증후군, 난소 기능부전, 갑상선 기능저하)이나 시상하부장애(뇌의 만복감 중추 장애시 나타난다.) 등 어떤 원인으로 인해 비만이 되는 증후성 비만이 있으며, 비만의 95%는 단순비만에 속한다.Obesity in humans includes excessive calorie intake, endocrine disorders, lack of exercise, and genetic factors. However, the main mechanism of development is an imbalance between energy intake and consumption. When energy consumption efficiency is poor, obesity occurs due to fat accumulation. Simplicity (essential) obesity and endocrine diseases (insulin-dependent diabetes mellitus, cushing syndrome, ovarian insufficiency, hypothyroidism) or hypothalamic disorders (which appear when the brain's bloat is central). Symptomatic obesity due to some causes obesity, 95% of obesity is a simple obesity.
또한 비만은 체내 지방의 과다축적으로 인해 정상적 생리기능에 장애를 주고 당뇨병, 심혈관계 질환, 지질대사 이상, 암 등의 여러 가지 만성적 질환의 원인이 되는 것으로 알려져 있으며,In addition, obesity is known to cause abnormal physiological function due to excessive accumulation of fat in the body and cause various chronic diseases such as diabetes, cardiovascular disease, lipid metabolism abnormality, and cancer.
현재 개발되어 시판되고 있는 비만치료제로는 시상하부를 자극하여 식욕을 억제시키는 식욕억제제인 시부트라민(sibutramine), 펜터민(phentermine), 디부틸푸로피온(diethylpropion), 펜디메트라진(phendimetrazine), 벤즈페타민(benzphetamine), 메탐페타민(methamphetamin)이 있으며 췌장 지방분해효소 저해제를 이용하여 섭취된 지방의 흡수를 억제시키는 오리스탓트(orlistat)가 대표적이며 또한 알파 글루코다이즈 억제제(α-glucosidase inhibitor)로 당뇨병에 사용하는 아카보스(acarbose)가 비만치료제로 사용하지만 현재까지 개발된 의약제적 비만치료제는 탁월한 효능은 보이지만 불면증, 신경불안, 두통, 빈맥, 혈압상승, 위장장애, 과민증, 담즙분비장애, 지용성 비타민 흡수억제 등의 심각한 부작용이 동반되는 것으로 알려져 있다.Currently developed and commercially available obesity treatments include appetite suppressants that stimulate the hypothalamus to suppress appetite, sibutramine, phentermine, dibutylpropion, phendimetrazine, and benzpetta There are benzphetamine and methamphetamin, orlistat, which inhibits the absorption of fat ingested using pancreatic lipase inhibitors, and alpha-glucosidase inhibitor. Although acarbose is used as an anti-obesity agent, the medicinal obesity drug developed so far shows excellent efficacy but insomnia, nervousness, headache, tachycardia, increased blood pressure, gastrointestinal disorders, irritability, bile secretion disorders, and fat-soluble vitamin absorption suppression. It is known to be accompanied by serious side effects.
많은 연구개발에도 불구하고 현재까지 부작용이 없는 의과학적 치료법이나 약물이 개발되지 못해 최근에는 부작용이 없는 천연 물을 사용한 항비만 기능성식품 또는 제품개발이 크게 관심을 받고 있다.Despite many research and development, the development of anti-obesity functional foods or products using natural products without side effects has recently been greatly attracted since no medical treatments or drugs have been developed.
비만의 개선을 위해서는 단순히 식욕억제기능, 췌장 지방분해효소 저해제를 이용하여 섭취된 지방의 흡수를 억제시키는 정도로는 근본적 치유나 개선이 이루어질 수 없으므로 비만에 관한 연구가 수행되면서 다양한 bio-marker들이 제시되고 있다.In order to improve obesity, a simple bio-marker is proposed as a study on obesity, because a fundamental curative or improvement cannot be achieved by simply suppressing appetite function and inhibiting absorption of fat ingested using pancreatic lipase inhibitor. have.
현재까지 본 출원의 연구결과로 보면 항비만 효능에 대한 검증을 위해서는,So far, the results of the present application for the verification of anti-obesity efficacy,
첫째, 혈액내 지질함량을 개선시킬 수 있는 소재발굴이 필요하며, 이는 체중이 많이 나갈수록 혈중의 지질농도가 높아지게 되며 특히 혈액내 총 콜레스테롤 및 중성지방상승이 비만과 높은 상관관계를 가진다. 따라서 고지방식으로 비만을 유도한 동물성 실험에서 혈액내 중성지방 및 총 콜레스테롤의 함량을 낮추는 효과는 항비만 효능을 가진다고 할 수 있다.First, material extraction is needed to improve the lipid content in the blood, which means that the higher the weight, the higher the lipid concentration in the blood. In particular, the total cholesterol and triglyceride rise in the blood have a high correlation with obesity. Therefore, the effect of lowering the content of triglyceride and total cholesterol in the blood in the animal experiments that induced obesity in a high fat diet can be said to have anti-obesity effect.
둘째, 지방세포의 수와 크기를 개선시킬 수 있는 소재발굴이 필요하며, 체중 증가량과 복부내장지방은 양의 상관관계를 나타내며 지방세포의 크기는 체내 지방량과 유의적인 상관관계를 보인다. 따라서 지방세포의 수적변화 및 크기변화는 항 비만효능을 검증하기 위해서는 필수적 지표라 할 수 있다.Second, material extraction is needed to improve the number and size of fat cells, weight gain and abdominal visceral fat are positively correlated, and fat cell size is significantly correlated with body fat mass. Therefore, the change in the number and size of adipocytes is an essential indicator to verify the anti-obesity effect.
셋째, 세포내 지질대사 관련효소의 활성을 개선시킬 수 있는 소재발굴이 필요하며, 세포로 이동된 지질은 합성대사와 분해대사의 두가지 경로중 하나에 이용되어지게 되는데, 여러 가지 상황에 따라 분해대사에 관련된 효소의 활성이 증대되면 에너지소비를 촉진시키게 되고 합성대사에 관련된 효소의 활성이 증대되면 에너지 축적을 유도하게 된다.Third, material extraction is needed to improve the activity of intracellular lipid metabolism-related enzymes, and lipids transferred to cells are used in one of two pathways: synthetic metabolism and degradation metabolism. Increased activity of enzymes related to promote energy consumption and increase energy activity of enzymes involved in synthetic metabolism to induce energy accumulation.
본 발명은 상기에서 언급한 기술개발의 방향범주에서 시도된 발명이지만 본 발명과 관련성이 있는 종래기술의 구체적인 실시예를 알아보면, The present invention is an invention attempted in the above-mentioned direction of technical development, but looking at specific embodiments of the related art related to the present invention,
국내특허공보(등록번호 제10-0597036호)에는 "다이어트 영양조성물이 소개되어 있고 기술내용은 대두단백, 유단백, 식이섬유, 올리고당, 영양조성물에 산사자, 결명자, 감잎 및 월경자의 액기스, 콜라겐으로 이루어진 다이어트 영양조성물에 관한 것이고, 다른 종래기술로서 국내등록특허(등록번호 제10-0856241호)에는 "한천을 이용한 다이어트 식품조성물"이 소개되고 있으며, 기술의 내용인즉 한천, 카르시니아 감보시아, 난소화성 말토덱스트린, 각종 곡물, 유산균, 녹차, L-카르니틴, 백봉령, 황기, 어성초, 콩가루(콩단백), 신선초, 치커리, 채소, 다시마, 칡, 호박을 각각 체적비율로 배합한 다이어트식품에 관한 것이며 또 다른 종래기술로서 국내공개특허공보(공개번호특허 제10-2003-83347호)에 비만을 줄이거나 없애는 방법으로 "생식 및 선식 조성물"이 소개되고 있고 국내공개특허공보(공개번호특허 제10-1998-8055호)역시 "건강 식이요법"으로 곡물류의 군, 채소의 군, 버섯류의 군, 허브류의 군으로 조성된 다이어트 조성물들을 소개하고 있다.Domestic Patent Publication (Registration No. 10-0597036) "Diet nutrition composition is introduced and the technical content of soybean protein, milk protein, dietary fiber, oligosaccharides, nutritional composition of hawthorn, cassia, persimmon leaf and menstrual extract, collagen It relates to a diet nutrition composition, and as another conventional technology, a domestic diet patent (Registration No. 10-0856241) is introduced "a diet food composition using agar," the contents of the technology, namely agar, carcinia gambosia, Indigestible maltodextrin, various grains, lactic acid bacteria, green tea, L-carnitine, Baeknyeongryeong, Astragalus, Eoseongcho, Soybean powder, Soychocho, Chicory, Vegetables, Kelp, Soybean, Pumpkin As another conventional technology, "reproductive and gland composition" is introduced as a method of reducing or eliminating obesity in Korea Patent Publication (Publication No. 10-2003-83347). Korean Patent Publication (Publication No. 10-1998-8055) also introduces diet compositions composed of a group of cereals, a group of vegetables, a group of mushrooms, and a group of herbs as a "health diet."
상술한 종래기술들은 영양물질, 식물생약재, 기능성을 갖는 물질들로 구성된 다이어트식품이거나 조성물로서 각 구성물질의 성상이나 상태가 큰 차이가 있음에도 배합 또는 조성하는 기본적인 방법조차도 기재되어 있지 않고 다이어트식품이나 조성물을 구성하는 각각의 구성물에 대한 성분이 전혀 기재되어 있지 않을 뿐만 아니라 단순히 각 구성물을 나열 또는 배합으로 구성한 다이어트식품이나 조성물이라 할 수 있으므로 각각의 구성물질이 갖는 기능이나 효과이상의 것은 기대할 수 없는 다이어트식품이나 조성물이라 할 수 있다.The above-mentioned prior arts are diet foods or compositions consisting of nutritional substances, herbal medicines, and functional substances. Even though there is a great difference in the properties and conditions of each component, even the basic method of blending or composition is not described. Not only does not contain any ingredients for each of the components constituting the diet foods or compositions that consist of simply listing or combining each component, so that more than the function or effect of each component can not expect a diet food It may be referred to as a composition.
그밖에 이건 특허출원과 관련성이 큰 국내등록특허(등록번호 제10-891914호)의 "제품화 과정과 회향을 함유하는 식품생약제 조성물의 항비만 건강효능 검증에 관한 연구결과로 강원대에 의뢰하여 연구과정 및 연구결과에 따라 개량보완한 발명으로 먼저 생약제 추출에 있어 유효성분의 손실량을 최소화함과 동시에 항비만기능과 병행하는 보조적인 기능의 원활화에 대한 방법이나 수단 등이 보완되어야 하는 필요성을 갖게 된다. In addition, this is a research result on the anti-obesity health efficacy test of food and drug composition containing fennel, which is a Korean registered patent (Registration No. 10-891914) which is related to patent application. According to the results of the study, an improved and complementary invention first needs to minimize the loss of active ingredients in the extraction of herbal medicines, and at the same time, supplement the methods or means for the smoothing of the auxiliary functions in parallel with the anti-obesity function.
본 발명은 식물생약제를 이용한 다이어트용 식품의 제조방법을 제공함에 있으며 식물생약제로부터 각종 유효성분을 추출함에 있어 유효성분의 손실을 유발하 는 요인을 제거하므로서 유효성분의 회수율을 최대한 높힘과 동시에 우수한 항비만(다이어트)기능을 가지는 회향을 비롯한 제1군의 식물생약제 추출물과 혈압강하, 콜레스테롤 저하 및 원활한 대사기능 등 보조기능을 균형있게 수행하게 하므로서 인체의 각 기관을 동시에 활성화시키므로서 항비만 기능에 상승효과를 갖게 하는 제2군의 식물생약제 추출물로된 식물생약제를 이용한 다이어트용 식품의 제조방법을 제공함에 있다.The present invention provides a method for producing a diet food using a plant herbal medicine and by removing various factors causing the loss of the active ingredient in the extraction of various active ingredients from the plant herbal medicine to increase the recovery rate of the active ingredient to the maximum and at the same time excellent Elevated anti-obesity function by activating each organ of the human body at the same time by performing the balanced function of plant herbal medicine extract of the first group including fennel with obesity (diet) function, lowering blood pressure, lowering cholesterol and smooth metabolism It is to provide a method for producing a diet food using a plant herb extract of the second group of plant herb extracts to have an effect.
다이어트용 식품을 제조하기 위한 식물생약제를 선택함에 있어 전술한 실험결과에 근거를 두고 항비만(다이어트) 주기능을 갖는 회향(Fennel, Foeniculum Fractus)성분에 첨가하므로서 항비만기능을 증가시키는 제1군의 식품생약제와 회향 및 제1군의 식품생약제에 첨가하므로서 혈압강하, 콜레스테롤 감소, 원활한대사기능 등 보조기능을 균형있게 수행하므로서 인체의 각종 기관을 동시에 활성화시키므로서 항비만 기능에 간접적으로 상승효과를 부여케 하는 2군의 식물생약제를 선택하여 이들을 추출함에 있어 회향 84.91wt%와 1군의 식물생약제 중에서 선택되는 하나 이상의 식물생약제 9.43wt%, 2군의 식물생약제 중에서 선택되는 하나 이상의 식물생약제 5.66wt%로 조성된 전체생약제 조성물을 1차 증류수로 추출한 추출물을 압착하거나 원심분리하여 여과하므로서 1차 여액을 얻고 압착 또는 원심분리한 잔사 및 여과잔사에 알콜수용액을 첨가하여 추출하므로서 2차 추출액을 수득하여 1차 추출액과 2차 추출액을 혼합하므로서 식물생약제에 함유된 유효성분의 회수율을 높힌 혼합추출액을 농축시킨 농축추출액에 천연당액을 첨가하거나 농축추출액을 동결건조한 분말을 천연 결합제로 성형하여 구상, 환상으로 성형한 다이어트용 식품제법을 제공하므로서 본 발명의 목적을 달성할 수 있다.The first group to increase the anti-obesity function by adding to the fennel (Fennel, Foeniculum Fractus) component having an anti-obesity (diet) main function based on the results of the above experiment in selecting a plant herbal medicine for the production of diet food It is added to the food herbal medicine and fennel and the first group of food herbal medicine to balance the secondary functions such as lowering blood pressure, reducing cholesterol, and smooth metabolism, and by activating various organs of the human body at the same time, indirect synergistic effect on the anti-obesity function In selecting and extracting two groups of plant herbs to give them, fennel 84.91wt% and at least one plant herbicide selected from the group 1 plant herbs 9.43wt%, at least one plant herbicide selected from the group 2 plant herbs 5.66wt The total herbal composition composed of% was filtered by compressing or centrifuging the extract extracted with primary distilled water. The secondary filtrate was obtained by adding the first aqueous filtrate and extracting by adding the aqueous alcohol solution to the compressed and centrifuged residue and the filtered residue to increase the recovery rate of the active ingredient contained in the plant herbal medicine by mixing the primary and secondary extracts. The object of the present invention can be achieved by adding a natural sugar solution to the concentrated extract solution with concentrated mixed extract or by forming a freeze-dried powder of the concentrated extract with a natural binder to provide a food formulation for spherical shape and annular shape.
본 발명에 의한 식물생약제 추출물로된 다이어트용 기능성식품은 식물생약제에 함유된 유효성분의 손실을 최소화하므로서 유효성분의 함량이 높으며 회향 및 제1군의 식물생약제 추출농축액에 의한 지질대사와 관련된 효소중 LPL의 활성을 억제하여 혈중트리글리셀라이드의 체지방을 에너지원으로 사용케하여 비만개선과 예방의 효과로 우수한 항비만작용을 할 수 있고 제2군의 식물생약제의 성분과 작용에 의해 회향을 비롯한 제1군의 식물생약제의 항비만작용과 함께 보조적인기능을 균형있게 수행하므로서 인체의 각 기관을 동시에 활성화시키므로서 항비만기능의 상승효과를 갖게 하는 식물생약제를 이용한 다이어트용 식품이라 할 수 있다.Functional food for diet with plant herbal extract according to the present invention has a high content of active ingredients while minimizing the loss of active ingredients contained in plant herbal medicines, and among enzymes related to lipid metabolism by fennel and the first group of plant herbal extract concentrates. By inhibiting the activity of LPL, the body fat of triglyceride in blood can be used as an energy source, and it can have an excellent anti-obesity effect by improving and preventing obesity. The anti-obesity action of a group of herbal medicines of the group together with supplementary functions to balance the activation of each organ of the human body at the same time can be called a diet food using a herbal medicine that has a synergistic effect of anti-obesity function.
본 발명 다이어트식품에 사용되는 식물생약제는 항비만(다이어트)의 주기능을 갖는 회향 84.91중량%와 회향과 복합물로서 항비만기능을 증가시키는 정향, 사상자, 백출 또는 창출, 황기, 차전자, 결명자, 복령 중에서 선택되는 하나 이상의 제1군의 식물생약제 9.43중량%, 인체의 각 기관을 활성화시키는 보조적인 기능에 의해 간접적으로 항비만기능에 상승효과를 갖게하는 식물생약제로서 홍삼, 이의인, 시호, 택사, 저령, 적소두, 방풍, 오가피, 구기자, 진피 중에서 선택되는 하나 이상의 제2군의 식물생약제 5.66중량%로 구성되는 전 식물생약제 조성물의 10배중량에 해당하는 증류수와 함께 온도 60~70℃로 유지된 밀폐용기에서 24시간 추출하여 압착 여과하거나 원심분리 여과하여 1차 여과액을 얻고 앞 공정에서 발생된 생약제 잔사를 5배중량에 해당하는 60%의 알콜수용액에 침지한 상태에서 온도 78~83℃로 유지하여 5시간 추출하는 과정에서 알콜(에탄올)의 대부분을 증발시킨후 추출액을 압착여과하여 2차 여과액을 얻고 이를 1차 여과액에 혼합하여 감압농축시킨 추출농축액에 천연당을 첨가하여서되는 식물생약제를 이용한 다이어트용 식품이라 할 수 있다.Plant herb used in the diet food of the present invention is 84.91% by weight of fennel having the main function of anti-obesity (diet) and fennel and complexes to increase the anti-obesity function of cloves, casualties, whitening or creation, Astragalus, chacha, deficiency, 9.43% by weight of one or more first-class plant herbal medicines selected from Bokryeong, a plant herbal medicine that has an indirect synergistic effect on anti-obesity by an auxiliary function of activating each organ of the human body as red ginseng, Eui-in, Shiho, Taeksa Maintained at a temperature of 60-70 ° C. with distilled water corresponding to 10 times the weight of the whole plant herbal composition consisting of 5.66% by weight of at least one second group of plant herbicides selected from among aging, red bean curd, windproof, organza, wolfberry, and dermis Extracted from the sealed container for 24 hours, compressed filtration or centrifugal filtration to obtain the primary filtrate, 60 times the weight of the crude drug residue produced in the previous process 60 After immersing in the aqueous alcoholic solution of% and maintaining the temperature at 78 ~ 83 ℃ for 5 hours, the majority of the alcohol (ethanol) was evaporated and the extract was compressed and filtered to obtain a secondary filtrate. It may be referred to as a diet food using a plant herbal medicine by adding natural sugar to the extract concentrate concentrated under reduced pressure by mixing.
또한 본 발명은 상기 추출농축액을 동결건조방법으로 제조된 식물생약제 추출농축액의 분말에 천연결합제로서 꿀, 천연당, 알긴산염 중 하나를 첨가하여 구상, 환상으로 성형한 식물 생약제 추출물로된 다이어트용 식품도 포함되며, 천연결합제의 량을 5~10wt%가 적합하다.In addition, the present invention is a diet foods made of plant herbal extracts spherically shaped and annular by adding one of honey, natural sugars and alginate as a natural binder to the powder of the plant extracts prepared by the lyophilization method. It is included, the amount of natural binder is 5 ~ 10wt% is suitable.
상기 방법에서 증류수로 추출하는 온도나 알콜수용액으로 추출하는 온도는 가능한한 낮은 온도에서 추출하는 것이 유리하다. 압력과 함께 100℃이상의 고온에서 처리할 경우 특히 회향이나 정향 등의 발향물질은 물론이고 다른 식물생약제 중에서 비점이 낮거나 분해온도가 낮은 식물생약제 성분이 분해 소실되는 경우가 발생하게 되며 또한 각각의 식물생약제는 다양한 성분이 함유되어 있고 다양한 성분 중에는 물에 용해하는 성분과 유기용제(알콜)에 용해되는 성분이 함께 함유되어 있어 식물생약제 성분을 추출함에 있어 수용성 또는 용제 용해성의 성분의 과다에 따라 전 생약제성분을 군으로 구분하여 물만으로 추출하거나 용제(에탄올)만으로 추출하여 혼합추출액을 얻는 경우보다 식물생약제는 물로 1차 추출액을 얻고난 잔사를 알콜수용액으로 추출하여 2차 추출액을 얻은 다음 1차 추출액과 2차 추출액을 혼합한 혼합추출액을 얻는 것이 유효성분의 추출효율면에서 8~12%를 증가시킬 수 있어 유리하다 하겠다.In the above method, the extraction temperature with distilled water or the extraction with alcoholic solution is advantageously extracted at the lowest possible temperature. When processed at a temperature higher than 100 ℃ with pressure, especially plant-derived substances such as fennel and cloves, as well as other plant herbals, decomposition or loss of botanical components with low boiling point or low decomposition temperature may occur. The herbal medicine contains various ingredients, and among the various ingredients, both the water soluble component and the organic solvent (alcohol) component are contained together. Plant herbal medicines are obtained by distilling the ingredients into groups and extracting only with water or solvents (ethanol) to obtain a mixed extract. It is 8 ~ 1 in terms of extraction efficiency of the active ingredient to obtain a mixed extract mixture of secondary extracts. It can be increased by 2%.
그리고 식물생약제 추출잔사물에 알콜수용액을 첨가하여 열처리추출하는 경우 여기에서 사용된 알콜(에탄올)은 회수하여 농도를 조절하여 차기의 식물생약제 잔사물 추출에 이용되며 추출액의 감압농축은 압력 200~300Torr범위의 감압상태에서 온도 40~50℃로 유지시킨 상태에서 실시하며 추출농축액으로 얻을 수 있는 량은 생약제 투입량의 8w%를 얻을 수 있고 식물생약제, 물 및 알콜수용액의 합한 총처리투입량에 대해서 0.5wt%를 얻을 수 있다. 그밖에 추출농축액으로 냉동건조하여 분말화할 경우에는 상기 추출농축액을 금속제 또는 플라스틱제 평판 위에 살포하여 분산코팅하여 1~2mm 두께로 형성시킨 다음 -60~-70℃범위에서 냉동건조하면 해면상의 건조층을 얻을 수 있으며 이를 분쇄하여 5wt%이하의 수분함량으로하여 밀봉포장시킨다. 냉동건조하여 분말을 얻을 경우는 생약제 투입중량의 2wt%의 분말을 얻을 수 있고 총처리 투입량에 대해서 수분함량 5wt%의 0.125wt%의 분말을 얻을 수 있다. 환언하면 식물생약제 1000kg을 추출하면 80kg의 추출농축액을 얻을 수 있고 20kg의 분말을 얻을 수 있다.And in the case of extracting heat treatment by adding alcohol aqueous solution to the plant herbal extract residue, the alcohol (ethanol) used here is recovered and controlled to be used for the extraction of the next plant herbal residue, and the concentrated concentration of the extract is 200-300 Torr. It is carried out under the reduced pressure in the range of 40 ~ 50 ℃, and the extractable concentrate can obtain 8w% of the input of the herbal medicine and 0.5wt based on the total total treatment input of the plant herbal medicine, water and alcoholic aqueous solution. You can get%. In addition, in the case of powder drying by freeze drying with the extract concentrate, the extract concentrate is sprayed onto a metal or plastic plate and dispersed and coated to form a thickness of 1 to 2 mm, and then freeze-dried at a range of -60 to -70 ° C. It can be obtained and pulverized and sealed with moisture content of 5wt% or less. When the powder is obtained by freeze-drying, a powder of 2 wt% of the input weight of the herbal medicine can be obtained, and a powder of 0.125 wt% of 5 wt% of water content can be obtained with respect to the total treatment dose. In other words, if you extract 1000 kg of plant herbs, you can get 80 kg of extract concentrate and 20 kg of powder.
상기 다이어트용 식품제조방법에 사용된 식물생약제의 성분과 기능작용에 대하여 알아보면, 회향을 비롯한 정향, 사상자, 백출, 황기, 차전자, 결명자, 복령으 로 구성되는 제1군의 생약제들은 국내등록특허공보(등록번호 제10-891914호)에 상세하게 기재되어 있으며 홍삼 이의인, 시호, 택사, 저령, 적소두, 방풍, 오가피, 구기자, 진피의 군으로 되는 제2군의 식물생약제에 대해서 기술하면,If we look at the components and functional functions of the herbal medicines used in the diet food manufacturing method, the first group of herbal medicines consisting of fennel, clove, casualties, baekrye, Astragalus, chajeon, gyeongmyeong, Bokryong are registered in Korea. It is described in detail in the patent publication (Registration No. 10-891914), and describes the second group of plant herbal medicines which is a group of red ginseng opiate, shiho, taxa, geranium, red bean curd, windproof, ogapi, wolfberry, and dermis. ,
홍삼은 인삼을 쪄서 말린 것을 홍삼이라 하며 인삼과 같이 배당체, 인삼향성분(panacen), 폴리아세티렌계 화합물, 함질소성분, 폴라노이드, 비타민(B조), 미량원소, 효소, 항산화물질과 유기산 및 아미노산이 함유되어 있으며, Red ginseng is dried red ginseng and is called red ginseng. Like ginseng, glycosides, ginseng fragrances (panacen), polyacetylene-based compounds, nitrogen-containing compounds, polaroids, vitamins (group B), trace elements, enzymes, antioxidants, organic acids and Contains amino acids,
중추신경에 대해서 진정작용과 흥분작용이 있으며, 순환계에 작용하여 고혈압이나 동맥경화의 예방효과가 있다. 그러면서도 조혈작용과 혈당치를 저하시켜주고, 간을 보호하며, 내분비계에 작용하여 성행동이나 생식효과에 간접적으로 유효하게 작용하며, 항염 및 항종양작용이 있고, 방사선에 대한 방어효과, 피부를 보호하며 부드럽게 하는 작용도 있다.The central nervous system has sedation and excitement effects on the circulatory system, which has the effect of preventing hypertension or arteriosclerosis. It also lowers hematopoietic and blood sugar levels, protects the liver, and acts indirectly on sexual and reproductive effects by acting on the endocrine system, has anti-inflammatory and anti-tumor effects, protects against radiation, and protects the skin. It also works to soften.
홍삼은 효과 중 중요한 것은 어댑토겐(adaptogen)효과로서 주위 환경으로부터 오는 각종 유해작용인 눈병, 각종 스트레스 등에 대해 방어능력을 증가시켜 생체가 보다 쉽게 적응하도록 하는 능력이 있음이 과학적으로 입증되고 있다.Red ginseng has been scientifically proven to have the ability to adapt more easily to the body by increasing the ability to protect against various diseases such as eye disease, stress, etc., which are important effects of the adaptogen (adaptogen) effect from the environment.
시호는 묏미나리, 참나물이라고도 불려지며 성분으로는 전초와 뿌리에 사포닌, 플라보노이드, 쿠마린, 탄닌질 세스쿠이 테르펜락톤이 함유되어 있고 작용으로는 열내림작용, 이담작용, 스테롤과 성분과 α-스피나스테롤은 혈장 콜레스테롤함량은 줄인다.Shiho is also known as celery and green sprouts. Its components include saponins, flavonoids, coumarins, tannins, sesquiy terpenlactone, and its actions include heat-lowering, edema, sterols, and α-spinasterol. Decreases plasma cholesterol content.
택사는 질경이 택사라고도 부르며 여러해살이 풀이며 뿌리줄기에 정유, 수지, 아세틸콜린, 레찌딘, 아스파라긴을 비롯한 아미노산 많은량의 당, 피트스테 롤, 피트스테롤린, 기름(팔미틴, 스테아린, 올레인), 알카로이드와 많은량의 농마(23%), 단백질(7%)이 함유되어 있다. 최근에는 택사로부터 4고리트리테르페노이드인 알리솔, 그의 모노아세타르, 이피-알리솔A가 얻어졌다. Taxa is also called talc, perennial herb, perennial, with essential oils, resins, acetylcholine, lecidin, asparagine, high amounts of amino acids, sugars, pitsterol, pitsterol, oils (palmitin, stearin, olein), It contains alkaloids, plenty of horses (23%) and protein (7%). Recently, alisole, a monoacetar, and epi-alisol A, which are tetracyclic terpenoids, have been obtained from Taxa.
작용으로 뿌리줄기는 동물실험에서 오줌내기작용이 뚜렷하며 혈액에서 요소와 콜레스테롤의 농도를 낮춘다. 임상실험에서도 오줌내기작용이 있으며, 오줌을 통하여 요소와 염화물의 배설을 늘이고 당이 적게 나가도록 하는 기능이 밝혀졌다. 또한 동물실험에서 콜레스테롤을 섞은 단백먹이를 먹여 일으킨 지방간치료에 효과가 있으며 콜레스테롤 침착에 의한 혈관벽의 상처를 아물게하는 작용이 있다. 이러한 작용성분을 콜린, 레찌틴, 알리솔에 의한 것으로 보고 있다.Root stem is a pissing effect in animal experiments and lowers the concentration of urea and cholesterol in the blood. In clinical trials, there was a urinating effect, and urine was found to increase the excretion of urea and chloride and lower sugar content. In addition, it is effective in treating fatty liver caused by feeding protein mixed with cholesterol in animal experiments, and has a function to heal wounds of blood vessel walls caused by cholesterol deposition. These actives are believed to be due to choline, lecithin, and alisol.
저령은 참나무뿌리 혹버섯으로 가저시, 야저분, 풍수령이라고도 부르며, 균핵체는 가랑잎이 쌓인 얕은 땅속에서 생기며 생김새가 생강과 비슷하고 마디가 있는 덩어리로서 참나무과 식물 단풍나무과 식물, 오리나무, 자작나무, 소나무의 죽은 뿌리에 생긴다. 작용으로는 오줌량이 크게 늘어나며 오줌내기 작용은 콩팥에서 물과 전해질의 재흡수를 억제하기 때문에 나타난다. 개에게 주사하면 오줌량이 늘어나고 나트륨, 칼리움, 크롬이온의 배설을 늘린다. 동의치료에서는 오줌내기약, 콩팥질병, 열내림약으로 사용하여 왔다.It is called oak root or mushroom, and it is also called gnome, sperm and feng shui. The mycelium is formed in the shallow ground where the leaves are piled up, and its shape is similar to ginger, and it is a lump of oak, maple, birch and birch. , Occurs on the dead roots of pine trees. The action is to increase the amount of urine, and urinary action appears because it suppresses the reabsorption of water and electrolyte in the kidneys. Injections into dogs increase urine output and increase excretion of sodium, kalium and chromium ions. In motion therapy, it has been used as urine medicine, kidney disease, and fever medicine.
적소두는 붉은팥으로 붉은팥에는 2%의 수분, 0.75%의 기름, 0.7%의 지방산의 알칼리염, 0.27%의 사포닌 단백질(파제올린)이 함유되어 있다.Red beans are red beans, which contain 2% water, 0.75% oil, 0.7% fatty acid alkali salts, and 0.27% saponin protein (pazeolin).
지방산은 팔미틴산, 스테아린산, 알라긴산이며 사포닌은 물로 분해하면 사포게닌과 포도당, 아라비노르, 람노즈로된다. 질소화합물로는 아데닌, 트리고넬린염 산염, 콜린, 알란토닌 적은량의 크레아틴이 있고 비타민 B1, B2, PP가 있다. 동의치료에서는 오줌내기약 콩팥염, 황달 등에 사용하여 왔다.Fatty acids are palmitic acid, stearic acid and alaginic acid, and when saponin is broken down into water, it becomes sapongenin, glucose, arabinor and rhamnose. Nitrogen compounds include adenine, trigonelin hydrochloride, choline, and allantoin in small amounts of creatine and vitamins B 1 , B 2 , and PP. In motion therapy, urine drugs have been used for kidney, jaundice, and the like.
방풍은 여러해살이풀로서 가을에 캐서 뿌리를 말린 것을 말한다. 뿌리에 정유 0.23~0.88%의 쿠마린이 있다. 쿠마린성분 가운데에는 에둘틴이 있으며 동의치료에서는 풍과 머리아픔, 발한해열약으로 사용하여 왔다.Windproof is a perennial herb that is dried in the casserole in the fall. Root contains 0.23--0.88% coumarin essential oil. Etulin is one of the coumarin ingredients, and it has been used as an antipyretic medicine for wind, head pain and antiperspirant medicine.
오가피는 오화, 목골이라 부르기도하며 오가피나무 껍질을 오가피라고하며 오가피에는 배당체인 아칸토시트, 탄닌질 약7%, 정유, 비타민 A와 C, 정유에는 오가피나무껍질의 냄새나는 성분으로 4-메톡시살리찔알데히드가 함유되어 있고 기름은 팔미틴산, 아라킨산 리놀산의 글리세리드이다. 배당체성분은 아직 조성이 밝혀져 있지 않으나 리그난핵의 게닌과 여러가지 당으로 되어 있다. Ogapi is also called hwahwa, wooden bone. Ogapi bark is called Ogapi. Ogapi contains glycoside acantosheet, tannins about 7%, essential oils, vitamins A and C. It contains salicialdehyde and the oil is a glyceride of palmitic acid and arachnic linoleic acid. The glycoside component is not yet known in composition, but it is composed of lignin nucleogen and various sugars.
작용으로는 정신육체적 피로를 회복시키며 적응활성이 있다. 고지혈증 리습 거습약으로 사용된다.It works by recovering mental and physical fatigue and has adaptive activity. It is used as a hyperlipidemic humectant.
구기자는 구기자나무의 열매로서 성분으로는 비타민 0.1%, 카로티노이드인 제아크산틴이 함유되어 있고 열매껍질에는 피살리엔이 분리되었다. 최근에는 구기자나무에서 처음으로 생물학적 활성물질인 스코플레틴, 카포티노이드, 스테린도 분리되었는데 이것은 피살리엔과 β-스토스테린이다.Goji berries are the fruit of the Goji berry tree and contain 0.1% vitamin and zeaxanthin, a carotenoid. In recent years, the first biologically active substances, scoplatin, capotenoid and sterin, have also been isolated from goji berry, which is pisalien and β-stosterin.
잎에는 베타인, 다우코스테린, 아스코르빈산이 있으며 또한 회분에는 Si, K, Na, Ca, Ma, Fe, P, S, Zn, F 등이 확인되었으며,The leaves contain betaine, doucosterin, ascorbic acid, and also ash, Si, K, Na, Ca, Ma, Fe, P, S, Zn, F, etc.
구기자는 혈압은 낮추는 작용이 있으며, 베타인은 콜린의 생체대사 산물의 하나로서 지질 친화성물질이다. 베타인염산염은 콜린대사계에 메틸기 공급물질로 하지간 작용이 있다.Gojija has a function of lowering blood pressure, and betaine is a lipid affinity as one of the metabolites of choline. Betaine hydrochloride acts as a methyl-based feedstock for choline metabolism.
또한 피의 콜레스테린량을 줄이므로 동맥경화의 예방과 치료에 쓴다.It also reduces the amount of blood cholesterol, so it is used to prevent and treat arteriosclerosis.
진피는 귤나무의 열매껍질을 진피라 하며, 열매에는 레몬산을 주성분으로 하는 유기산이 1~3%있고 아스파라긴, 프롤린, r-아미노버터산이 함유되어 있으며, 열매껍질에는 정유와 헤스피리딘이 함유되어 있고 헤스피리딘은 헤스페레탄과 포도당, 람노즈로 물 분해된다.The dermis is the fruit peel of the tangerine tree, and the fruit contains 1 ~ 3% of organic acid mainly composed of lemon acid, asparagine, proline, r-aminobutyric acid, and the fruit peel contains essential oil and hesperidin. Hesperidin is hydrolyzed to hesperetane, glucose and rhamnose.
작용으로는 방향성 건위작용이 있고, 헤스페리딘을 비롯한 플라노이드성분은 비타민 P 활성을 가지며 이담작용을 가진다.Actions include aroma odor, and heperidine and other flanoid components have vitamin P activity and have an idiot effect.
이의인은 율무의 씨를 말린 것으로 씨에는 단백질 8~20%, 유지 2~8%, 탄수화물 50~78%, 회분 0.5~2.3%가 함유되어 있다. 단백질을 물분해한 아미노산은 로이찐 21%, 티로신 2%, 알라닌 0.5%, 페닐알라닌 1.2%, 글루타민산 15%, 아르기닌 17%, 트로핀 2%, 아스피라긴 0.2%, 히스티딘 0.15%, 트립토판 등이고 유지(기름)은 팔미틴산, 스테아린산, 미르스틴산, 씨스-8-옥타데짼산(코익신산)의 글리세리드이며, 비누화되지 않은 부분에는 β-시토스테롤, 약간의 α-시트스테롤, 캄페스테롤, 스티그마스테롤이 있다.The object is dried seeds of Yulmu, which contains 8-20% protein, 2-8% fat, 50-78% carbohydrate and 0.5-2.3% ash. The amino acids that hydrolyzed the protein were 21% leuchin, 2% tyrosine, 0.5% alanine, 1.2% phenylalanine, 15% glutamic acid, 17% arginine, 2% tropin, 0.2% aspirazine, 0.15% histidine, and tryptophan. (Oil) is a glyceride of palmitic acid, stearic acid, myristic acid, cis-8-octademic acid (coicic acid), and the unsaponified portion includes β-sitosterol, some α-citsterol, camphorsterol, and stigmasterol .
탄수화물의 대부분은 농마이고 회분에는 P, Mg, Mn, Ca, Fe, Al, Zn, Ba, Cu, Mo, Sn, Ni 등이 함유되어 있다.Most carbohydrates are farm horses, and ash contains P, Mg, Mn, Ca, Fe, Al, Zn, Ba, Cu, Mo, Sn, Ni and the like.
씨는 아세톤추출액에는 코익세놀리드 C38H70O4가 있다. 이 물질은 씨스-9-헥사 데짼산과 트란스-11-옥타데짼산이 한 분자씩 결합된 것이다. 씨에는 또한 콜린 약 150mg%(유리형 또는 결합형)와 유기산이 있다. 유기산의 35%는 버터산, 60%는 옥시프로피온산과 약간의 다른 유기산이다.Seed contains acetonitrile C 38 H 70 O 4 in the acetone extract. This material is a single molecule of cis-9-hexademic acid and trans-11-octademic acid. Seeds also contain about 150 mg choline (free or combined) and organic acids. 35% of the organic acids are butteric acid, 60% of oxypropionic acid and some other organic acids.
뿌리에는 스테아린산과 팔미틴산의 글리세리드로 된 기름, β-시토스테롤, r-시토스테롤, α-시토스테롤, 스티그마스테롤, 정유 0.1%, 코익솔(C8H7O3N, 6-메톡시벤즈옥사졸론, 녹음점 151~152℃)이 있다.Roots contain stearic and palmitic glyceride oils, β-sitosterol, r-sitosterol, α-sitosterol, stigmasterol, essential oils 0.1%, Coixsol (C 8 H 7 O 3 N, 6-methoxybenzoxazolone, greening Point 151-152 degreeC).
작용으로는 씨의 단백질함량은 벼과 식물들인 입쌀이나 밀보다 높고 로이찐을 비롯한 필수아미노산이 많다. 이밖에도 기름과 미량원소를 비롯하여 사람의 영양에 좋은 성분들이 있다.In terms of action, the protein content of seeds is higher than rice and wheat, which are plants and rice, and there are many essential amino acids, including leucine. In addition, there are other ingredients that are good for human nutrition, including oils and trace elements.
씨는 또한 항염증작용, 과콜레스테린혈증을 낮추는 작용이 있다. 코익세놀리드는 에를리히복수암에 대한 증식억제작용이 있다. 이밖에도 씨의 약리작용은 많이 검토되었으나 연구자들에 따라 다른 견해를 가지고 있다.Seed also has anti-inflammatory, lowering hypercholesterolemia. Coixenolide has a proliferation inhibitory effect on Erlich's multiple cancer. In addition, the pharmacological action of seeds has been examined a lot, but researchers have different opinions.
뿌리에서 얻은 코익솔은 아픔멎이작용, 진정작용이 있으며 작용세기는 코익솔 100mg/kg에 아미노필린 145mg%가 해당된다. 또한 코익솔은 혈당량을 줄인다.Coixol obtained from the root has pain and sedative action, the strength of the action corresponds to 100mg / kg of Coixol 145mg% aminophylline. Coixol also reduces blood sugar levels.
이상의 작용들은 급성실험에서 얻어진 것들이며 만성실험과 임상실험에서는 거의 검토되지 못하였다.These actions were obtained in acute trials and were rarely examined in chronic and clinical trials.
씨는 보약으로 오래전부터 써왔다. 동의치료에서는 염증약, 오줌내기약, 배농약, 아픔멎이약으로 붓기, 곪는질병, 신경통, 관절아픔에 쓴다. 또한 사마귀를 떼는데도 쓴다.Mr. has been writing for a long time. In motion therapy, it is used for swelling, swelling diseases, neuralgia, and joint pain with inflammatory medicine, urine medicine, pear pesticide, and pain medicine. It is also used to remove warts.
뿌리는 민간에서 벌레떼기약으로 쓰며 신경아픔과 관결염에 쓴다.Roots are used as insect repellent in the private sector and used for nerve pain and arthritis.
코익솔은 신경아픔에 주사하기도 한다. 율무쌀로 밥이나 떡을 만들어 오래 먹으면 몸이 건강해진다고 한다.Coixol can also be injected into nerve pain. It is said that if you make rice or rice cake with Yulmu rice and eat it for a long time, you will be healthy.
율무씨 달임약(10~30:200)-하루 3번에 나누어 먹는다. 전염성 사마귀나 혹(molluscum contagiosiosum)치료에 쓴다.Yulmu's Decoction (10 ~ 30: 200) -Dining three times a day. Used to treat infectious warts or bumps (molluscum contagiosiosum).
본 발명실시를 위한 작업과정 및 회향(Fennel, Foeniculum Fractus)을 함유하는 식물생약제 조성물의 항비만 건강효능검정에 관한 연구에 관한 연구용역(강원대학교 강원 웰빙특산물 산업화 지역혁신센터)결과에 따른 회향과 회향혼합물의 추출을 첨가했을때 세포내에서 지방축적의 억제와 관련된 효소들의 활성변화 및 지방분해 이용의 촉진과 관련된 효소들의 활성변화정도를 측정하여 항비만효능을 실시예(1)로 평가하였다.A study on the study on anti-obesity health efficacy test of plant herbal composition containing Fennel (Fennel, Foeniculum Fractus) for the practice of the present invention (Fennel and according to the results of Kangwon National University Well-being special product industrial innovation center) When the extract of the fennel mixture was added, the anti-obesity effect was evaluated in Example (1) by measuring the activity change of enzymes related to inhibition of fat accumulation in cells and the activity change of enzymes related to the promotion of lipolysis use.
실시예(1)Example (1)
구체적으로는 회향단독의 식물생약제 또는 회향 90중량부에 사상자, 정향, 백출 또는 창출, 황기, 차전자, 결명자, 복령으로 구성되는 1군의 식물생약제 중에서 선택되는 하나 이상의 생약제를 첨가해서 되는 1군 식물생약제 10중량부(사상자 5: 정향 3: 백출 2)로 상술한 방법에 따라 1차 추출 및 2차 추출하여 혼합추출액을 얻고 이를 농축한 추출농축액으로 실험하였다.Specifically, a group consisting of one or more herbal medicines selected from one group of herbal medicines consisting of casualty, cloves, white extract or creation, Astragalus, chacha, lame, and Bokryong to 90 parts of fennel alone The plant extract was 10 parts by weight (case 5: clove 3: white extract 2) according to the above-described method to the primary extraction and secondary extraction to obtain a mixed extract and was tested with the concentrated extract concentrate.
1. 항비만효능 실험결과.1. Anti-obesity test results.
1) In vitro 실험.1) In vitro experiment.
회향 또는 회향함유 혼합 추출물 첨가한 실험군을 첨가하지 않은 대조군과 비교한 결과는 아래와 같이 나타났다.The results of the comparison with the control group without the addition of the fennel or fennel-containing extracts were as follows.
(1) 지질대사관련 주요 효소의(Key enzymes) 활성변화.(1) Changes in the activity of key enzymes related to lipid metabolism.
2) In vivo(동물실험)2) In vivo (animal experiment)
고지방식이를 섭취한 회향(Fennel) 섭취군을 고지방식이만을 섭취한 대조군과 비교한 결과는 다음과 같다.(실험 생쥐에게 11주 동안 고지방을 섭취시키고 후반 6주 동안 회향(Fennel)을 섭취시켰음.)The results of comparing the high-fat diet Fennel intake group with the high-fat diet only control group were as follows. I made it.)
(1) 체중 및 부고환 지방, 간 조직 무게.(1) Body weight and epididymal fat, liver tissue weight.
(2) 혈장 지질 및 glucose 함량.(2) plasma lipid and glucose content.
(3) 부고환 지방세포 크기.(3) epididymal adipocyte size.
고지방식이만을 섭취한 대조군과 비교하여 21.41% 감소.21.41% reduction compared to the control group fed only high-fat diet.
(4) 지질대사 Key enzyme 활성 변화.(4) Changes in key enzyme activity of lipid metabolism.
상기 실험결과를 요약하면,To summarize the results of the experiment,
* In vitro 실험결과는 회향추출물 또는 회향 혼합추출물(회향 90, 사상자 5, 정향 3 및 백출 2중량부)의 첨가는 Lipoprotein lipase(LPL)의 활성을 억제하여 혈중트리그리세라이드(triglyceride)의 세포내 유입을 저하시켰으며 HSL을 조절하여 지방조직의 저장지방의 분해를 촉진하여 체지방을 감소시키고 ACS의 효소를 활성화 시켜 유입된 지방산의 Catabolic Pathway를 촉진하여 지방산을 에너지원으로 사용케하여 비만개선과 예방에 효과적임을 알 수 있고 또한 CAT효소의 활성에는 크게 영향을 미치지 않았지만 다른 효소활성이나 동물실험의결과 다른 작용기전에 의해 항비만 효능이 있는 것으로 판단된다.* In vitro experiments showed that the addition of fennel extract or fennel extract (Fennel 90, casualty 5, cloves 3, and 2 parts by weight) inhibited the activity of Lipoprotein lipase (LPL), resulting in intracellular triglyceride Reduces inflow and regulates HSL to promote the breakdown of stored fats in adipose tissue to reduce body fat and activate enzymes of ACS to promote catabolic pathway of imported fatty acids to use fatty acids as energy sources to improve obesity and prevent In addition, it did not significantly affect the activity of CAT enzyme, but it was judged to have anti-obesity effect by other enzyme activity or other experimental mechanisms.
* In vivo 실험결과는 고지방식이가 체중, 간조직, 부고환 지방의 무게를 증가시켰으며 회향의 물농축 추출물이 간 조직의 지방축적을 억제 또는 분해하여 비만 개선에 효과가 있으며 또한 혈장지질 실험결과 회향의 물농축 추출물이 중성지방의 축적을 억제하여 비만에 의해 유발되는 심혈관계 질환의 위험성을 줄여줄 것으로 생각된다.* In vivo test results showed that high-fat diet increased the weight of body weight, liver tissue and epididymal fat, and water extract of fennel inhibited or decomposed fat accumulation in liver tissue, which was effective in improving obesity. Fennel extract is thought to reduce the accumulation of triglycerides and reduce the risk of cardiovascular diseases caused by obesity.
실시예(1)의 실험결과에서 In vivo(동물실험)에서 나타난 바와 같이 대부분의 항목에서 우수한 항비만효과를 기대할 수 있으나 혈장지질함량의 감소효과가 적고 이로 인해 실험쥐의 혈압측정시 혈압강하효과가 현저하지 않으며 소변이나 대변 등 배설물이 대조군에 비해 많지 않은 결과를 알 수 있었다.As shown in the in vivo (animal experiment) in the experimental results of Example (1), most of the items can be expected to have an excellent anti-obesity effect, but the effect of reducing the plasma lipid content is low, and thus the blood pressure lowering effect in the blood pressure measurement of the mice The results were not significant, and urine or faeces and feces were not much higher than the control group.
이와 같은 문제점을 보완하기 위해 식물생약제의 성분 및 그 기능작용을 문헌을 통해 발췌하고 이를 수많은 실험을 통해 전술한 홍삼, 이의인, 시호, 택사, 저령, 적소두, 방풍, 오가피, 구기자, 진피로 구성되는 제2군의 식물생약제를 선택하였다.In order to supplement the above problems, the components and functional functions of the herbal medicines are extracted from the literature, and these are composed of red ginseng, uiin, shiho, taeksa, ghost, red bean curd, windproof, organza, goji berry, and dermis through numerous experiments. A second group of plant herbs was selected.
실시예(2)Example (2)
실시예(1)의 식물성생약제 조성물(회향 84.91wt%에 제1군의 식물생약제 군에서 선택되는 하나 이상의 식물생약제 9.43wt%)에 상기 제2군의 식물생약제 중에서 선택되는 하나 이상의 식물생약제 5.66wt%(여기서는 홍삼 2.83wt%, 오가피 1.89wt%, 구기자 0.94wt%)를 첨가하여 상술한 방법에 따라 추출농축액을 얻었다.5.66 wt% of the plant herbal compositions of Example (1) (84.91 wt% fennel at least one plant herbicide selected from the first group of plant herbicides) and at least one plant herbicide selected from the second group of plant herbicides. % (Here red ginseng 2.83wt%, Ogapi 1.89wt%, wolfberry 0.94wt%) was added to obtain an extract concentrate according to the method described above.
이와 같은 추출농축액으로 상술한 항비만효능 실험에 따라 실험한 결과 혈장지질 및 글루코스함량은 표(1)과 같은 실험결과를 얻었다.Plasma lipid and glucose content of the extract concentrate was tested according to the anti-obesity efficacy test described above.
표(1) 혈장지질 및 글루코스함량.Table (1) Plasma lipid and glucose content.
상기 표(1)에 나타난 바와 같이 실시예(1)의 추출농축액으로 실시한 실험결과에서 나타난 형장지질 및 글리세라이드, 글루코스의 감량에 비해 실시예(2)의 추출농축액을 추가시켜 실시한 실험결과에서 고지방식이만을 섭취한 대조군과 비교한 결과 혈장지질 및 글리세라이드, 글루코스함량을 현저하게 감소시키므로서 실험결 과에서 실험생쥐의 혈압도 현저하게 낮출 수 있었으며 또한 실시예(2)의 추출 농축액으로 실시예(1)의 실험결과에서 나타난 상기 표(1)의 항목을 제외한 다른 항목을 시험한 경우 현저한 차이가 없고 또한 제2군의 식물생약제중 어느 것이든 6wt%범위로 선택할 경우 큰 차이가 없으므로 제2군의 식물생약제를 실시예(1)의 식물생약제 조성물에 첨가하므로서 실시예(1)의 미흡한 점을 보완한 본 발명의 실시예라 할 수 있다.As shown in the above Table (1), compared with the loss of the form lipid and glycerides and glucose shown in the experimental results of the extraction concentrate of Example (1), the extraction result of the experiment was performed by adding the extract concentrate of Example (2) As a result of significantly reducing plasma lipids, glycerides and glucose content as compared with the control group ingesting only the dietary formula, blood pressure of the experimental mice was significantly reduced in the experimental results, and the extract concentrate of Example (2) was used. In case of testing other items except the items in Table (1) shown in the experimental results of (1), there was no significant difference in selecting any of the plant herbicides of the second group in the range of 6wt%. By adding the plant herbal medicine of the group to the plant herbal composition of Example (1) it can be said to the embodiment of the present invention to compensate for the lack of the embodiment (1).
상기 실시예(1)에서 나타난 바와 같이 회향을 비롯한 제1군의 식물생약제 농축 추출액은 지질대사와 관련된 효소중 LPG의 활성을 억제하여 혈중 트리글리셀라이드의 세포내 유입을 저하시켰으며, HSL을 조절하여 체지방을 감소시키고 ACS의 효소를 활성화시켜 지방산을 에너지원으로 사용케하여 비만개선과 예방의 효과를 항비만작용을 할 수 있고 회향을 비롯한 제1군의 식물생약제에 첨가되는 제2군의 식물생약제들은 전술한 제2군의 식물생약제의 성분들에 의하여 발생되는 기능이나 작용과 같이 대부분이 잉요작용(오줌내기작용), 이담작용과 같이 원활한 배설대사작용과 혈장 콜레스테롤함량을 줄이는 작용, 콜레스테롤감소에 따른 혈압을 낮추는 기능과 작용으로 회향을 비롯한 제1군의 식물생약제의 항비만작용과 함께 보조적인 기능을 균형있게 수행하므로서 인체의 각기관을 동시에 활성화시키므로서 항비만기능의 상승효과를 갖게 하는 식물생약제 추출물로된 다이어트용 식품이라 할 수 있다.As shown in Example (1), the concentrated plant extracts of the first group, including fennel, inhibited the activity of LPG in enzymes related to lipid metabolism, lowered the intracellular influx of triglyceride in the blood, and regulated HSL. Reduce body fat and activate enzymes of ACS to use fatty acids as energy sources for anti-obesity effects of improving obesity and preventing obesity, and the second group of plants added to the first group of herbal medicines including fennel Herbal medicines, such as the function or action caused by the components of the second group of plant herbal medicines, such as the urinary action (peeing action), smooth excretion metabolism action, such as diarrhea effect, reducing plasma cholesterol content, cholesterol reduction It is a function and action of lowering blood pressure according to the anti-obesity action of the first group of herbal medicines including fennel and ancillary functions Can be active at the same time as the row hameuroseo because every organ of the body, wherein the food for the stand as a herbal plant extracts that have a synergistic effect of obesity functionality diet.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090096162A KR100948281B1 (en) | 2009-10-09 | 2009-10-09 | The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090096162A KR100948281B1 (en) | 2009-10-09 | 2009-10-09 | The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100948281B1 true KR100948281B1 (en) | 2010-03-18 |
Family
ID=42183486
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090096162A KR100948281B1 (en) | 2009-10-09 | 2009-10-09 | The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100948281B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101159116B1 (en) * | 2011-03-25 | 2012-06-25 | 임세규 | The method of preparing food for diet using madicin-materials of plants |
CN102526264A (en) * | 2012-01-04 | 2012-07-04 | 山东省中医药研究院 | Chinese medicinal preparation with blood fat reducing effect and preparation method thereof |
KR101487770B1 (en) * | 2012-06-28 | 2015-01-30 | 동신대학교산학협력단 | Antiobestic composition mixed with extract of pear and medicinal herbs and manufacturing method thereof |
KR20190028582A (en) * | 2017-09-08 | 2019-03-19 | 안동대학교 산학협력단 | Sealed and heat-treated zinger having anti-oxidant activity and anti-diabetes activity, and its manufacturing methods |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030064714A (en) * | 2002-07-17 | 2003-08-02 | 손종업 | Process for preparing uncooked food pills using uncooked food materials |
-
2009
- 2009-10-09 KR KR1020090096162A patent/KR100948281B1/en not_active IP Right Cessation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030064714A (en) * | 2002-07-17 | 2003-08-02 | 손종업 | Process for preparing uncooked food pills using uncooked food materials |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101159116B1 (en) * | 2011-03-25 | 2012-06-25 | 임세규 | The method of preparing food for diet using madicin-materials of plants |
CN102526264A (en) * | 2012-01-04 | 2012-07-04 | 山东省中医药研究院 | Chinese medicinal preparation with blood fat reducing effect and preparation method thereof |
KR101487770B1 (en) * | 2012-06-28 | 2015-01-30 | 동신대학교산학협력단 | Antiobestic composition mixed with extract of pear and medicinal herbs and manufacturing method thereof |
KR20190028582A (en) * | 2017-09-08 | 2019-03-19 | 안동대학교 산학협력단 | Sealed and heat-treated zinger having anti-oxidant activity and anti-diabetes activity, and its manufacturing methods |
KR101978507B1 (en) | 2017-09-08 | 2019-05-14 | 안동대학교 산학협력단 | Sealed and heat-treated zinger having anti-oxidant activity and anti-diabetes activity, and its manufacturing methods |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zaini et al. | Kundur [Benincasa hispida (Thunb.) Cogn.]: A potential source for valuable nutrients and functional foods | |
CN1271083C (en) | Composition, extraction process and use of total triterpene sapogenin extracted from bamboo | |
US9301987B2 (en) | Anti-adipogenic compositions containing Piper betle and Dolichos biflorus | |
KR20100042337A (en) | The composition of traditional oriental medicines for reheumatoid arthritis and the method of preparing medicine for it | |
KR101751398B1 (en) | Composition comprising Angelica gigas Nakai, Cornus officinalis, Cervi Parvum Cornu, Red ginseng, Rehmanniae Radix Preparata, Aquilaria agallocha Roxburgh and Honey for anti-inflammation | |
KR20130104692A (en) | Composition foranti-obesity using extract of crataegi fructus | |
KR20160133811A (en) | Breeding Method for Crickets Comprising Ginsenoside Type Saponin and Polysaccharide from Panax ginseng and their Extracts and Food Composition | |
KR100948281B1 (en) | The method of preparing the functional food for diet using extractive extracted from madicin-materials of plants | |
CN103749821B (en) | A kind of gynostemma pentaphylla health-care tea improving immunity and preparation method thereof | |
KR101245345B1 (en) | Germinated brown rice for prevention of obesite and method of production thereof | |
KR101788253B1 (en) | Composition for improving male sexual function comprising the extract of Alpinia Officinarum, Smilacina Japonica & Black Garlic | |
KR20110045371A (en) | Composition comprising extracts of Radix Smilax china, Paecilomyces japonica and Momordica charantia for hypoglycemic agent] | |
KR101829810B1 (en) | Fermented composition containing both forage barley and medicinal herbs extract material, and a preparation method thereof | |
Lal et al. | Nigella (Nigella sativa L.), a novel herb can cure many diseases: A review | |
CN106798854B (en) | Phyllanthus emblica leaf and preparation method thereof | |
KR20200025245A (en) | Preparation for improving blood circulation comprising mixed oriental medicinal extracts | |
CN107812115A (en) | A kind of Chinese medicine composition for treating diabetes | |
US20040185124A1 (en) | Health food and antitumor agent | |
KR20030053417A (en) | Health food composition which contains Saururus chinensis Baill. and others | |
CN112006136A (en) | Double-ginseng and dendrobium tea for improving abnormal blood sugar and preparation method thereof | |
KR20170024689A (en) | Food composition for bowel movement promotion and diet using herbal material | |
KR101894540B1 (en) | Composition for improving coenzyme Q10 with extract of Pinellia ternata, Atractylodes macrocephala, Gastrodia elata, Citrus unshiu peel, Poria cocos, Crataegus pinnatifida, Siegesbeckia pubescens Makino and Coptis japonica Makino | |
KR20240097072A (en) | Dietary food manufacturing method with natural binder added | |
KR20170029764A (en) | Garlic extracts, egg yolk extracts and sulfur mixture to back out of the prevention of cardiovascular, cerebrovascular and other circulatory organ system disease, for the inclusion of active ingredients and treatment of functional foods, improvement and the manufacturing method. and Health functional food, organic sulphur (MSM)as active ingredients composition | |
Jaiswal et al. | A Review on Portulaca oleracea (Nonia bhaji): A wonderful weed of Chhattisgarh |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130312 Year of fee payment: 4 |
|
LAPS | Lapse due to unpaid annual fee |